Krystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024. In the quarter to June 2026, revenue grew 24.1%, EPS grew 39.1% and free cash flow grew 40.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow KRYS
Krystal Biotech, Inc. (KRYS) Piotroski F-score
Krystal Biotech, Inc.'s Piotroski F-score for fiscal 2025 is 7 out of 9: 7 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 7 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 17.14% | 9.51% | Pass | 1 |
| Positive operating cash flow | 200.87m | 123.42m | Pass | 1 |
| Rising return on assets | 17.14% | 9.51% | Pass | 1 |
| Cash flow above net income | (3.97m) | 34.26m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 9.95 | 7.28 | Pass | 1 |
| No new shares issued | 28,944,000 | 28,592,000 | Fail | 0 |
| Rising gross margin | 94.08% | 93.09% | Pass | 1 |
| Rising asset turnover | 0.33 | 0.31 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 7 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| KRYS Krystal Biotech, Inc. | 7 |
| BMRN BioMarin Pharmaceutical Inc. compare | 5 |
| KYMR Kymera Therapeutics, Inc. compare | 4 |
| IBRX ImmunityBio, Inc. compare | 4 |
| PTGX Protagonist Therapeutics, Inc. compare | 4 |
| CYTK Cytokinetics, Incorporated compare | 2 |
| PCVX Vaxcyte, Inc. compare | — |
| MDGL Madrigal Pharmaceuticals, Inc. compare | — |
| CAI Caris Life Sciences,�Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover